A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
A Phase 1/1b, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Subjects With Chronic Hepatitis B (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)
Sponsor: Aligos Therapeutics
Terminated
Single doses demonstrated an acceptable safety profile and antiviral activity at all doses evaluated.
Other terminated trials from Aligos Therapeutics
Other Chronic Hepatitis B trials with similar outcome
A PHASE1 clinical study on Chronic Hepatitis B, this trial is terminated or withdrawn. The trial is conducted by Aligos Therapeutics and has accumulated 8 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Dec 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jun 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aligos Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .